Five Potential Blockbuster Oncology Approvals To Look Out For In 2023

With help from Biomedtracker, Scrip takes a look at five drug candidates in oncology poised to win a US thumbs up next year. These novel assets, including three bispecific antibodies, could attract blockbuster figures, according to industry observers.    

Piggy Money
These Pipeline Drugs Could Exceed $1bn In Sales • Source: Shutterstock

One of three CD20 X CD3 bispecific antibody candidates striving for a 2023 thumbs up in late-stage diffuse large B-cell lymphoma (DLBCL), Genmab A/S and partner AbbVie Inc.’s epcoritamab is set to be filed in the EU later this year. The firms are also preparing for a US filing in large B-cell lymphoma. 

While chimeric antigen receptor (CAR) T-cell drugs such as Kite Pharma’s Yescarta (axicabtagene ciloleucel) have recently won approval in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

ASCO: Kite’s Glioblastoma CAR-T Highlights Solid Tumor Progress

 

The company presented Phase I data for CART-EGFR-IL13Rα2, showing patient responses in the notoriously hard-to-treat and deadly brain cancer.

Will Pfizer Walk Away From Arvinas After PROTAC Disappointment?

 

Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.

ASCO: Carvykti Data Raise Possibility Of Myeloma Cure

 

J&J presented data at the American Society of Clinical Oncology meeting showing more than five-year disease- and therapy-free survival, but a myeloma working group will need to define what makes a cure.

Merus Raises $300m After ASCO Success

 

The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.

More from Therapy Areas

Will Pfizer Walk Away From Arvinas After PROTAC Disappointment?

 

Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.

Lyra Eyes US Filing For LYR-210 After Surprise ENLIGHTEN 2 Win

 

In a turn of fortunes, Lyra Therapeutics has reported positive Phase III results for LYR-210 in chronic rhinosinusitis, boosting hopes for US approval. The company plans to submit an NDA and pursue further trials, but its cash position is precarious.

Ascletis Plans China Submission After Positive Denifanstat Phase III Acne Results

 

Once-daily oral FASN inhibitor denifanstat meets all endpoints in a Chinese Phase III trial for moderate-to-severe acne, paving the way for a regulatory submission in China.